Stock comparison
IDEXX Laboratories
InMode
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
INMD
InMode
Market cap
$870.55M
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | INMD | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 56C | IDXX |
| Benjamin Graham | 80A | 52C | IDXX |
| Philip Fisher | 75B | 46D | IDXX |
| Peter Lynch | 71B | 24F | IDXX |
| Joel Greenblatt | 83C | 27F | IDXX |
| Charlie Munger | 87A | 58C | IDXX |
| Terry Smith | 84A | 59C | IDXX |
Side-by-side metrics
| Metric | IDXX | INMD |
|---|---|---|
| Market cap | $44.12B | $870.55M |
| P/E (TTM) | 39.0x | 10.0x |
| EV/EBIT | 31.6x | 5.6x |
| ROIC (TTM) | 40.66% | 10.11% |
| Gross margin | 62.05% | 77.84% |
| Net margin | 24.63% | 23.27% |
| Revenue CAGR 5y | 7.56% | 0.89% |
| EPS CAGR 5y | 10.79% | -8.07% |
| Debt / Equity | 0.7x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- EPS CAGR 5y10.79%vs -8.07%+175%
- Market cap$44.12Bvs $870.55M+98%
- Revenue CAGR 5y7.56%vs 0.89%+88%
- ROIC (TTM)40.66%vs 10.11%+75%
INMD leads on
- Debt / Equity0.0xvs 0.7x+99%
- EV/EBIT5.6xvs 31.6x+82%
- P/E (TTM)10.0xvs 39.0x+74%
- Gross margin77.84%vs 62.05%+20%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.